The efficacy and safety of a taxane-based chemotherapy regimen combined with a PD-1 inhibitor in HNSCC: a multicenter real-world study

Table 4 Efficacy Data of First-Line treatment regimens in selected studies on R/M HNSCC

Study Title	Study Population	Group	Patients(n)	ORR(%)	mPFS(Month)	mOS(Month)
		Group 1: K	301	16.9	2.3	11.5
KEYNOTE-048 [10]	Global	Group 2: Cetuximab + PF	300	36.0	5.1	10.7
		Group 3: K + PF	281	36.3	4.9	13.0
KEYNOTE-B10 [26]	US	Single-arm: K + Carboplatin + Paclitaxel	101	49.0	5.6	13.1
Black, C. M [27]	US	Single-arm: K + Platinum-based drug + Paclitaxel	83	NA	8.7	14.9
Fuereder, T [28]	Austria	Single-arm: K + Docetaxel	22	22.7	5.8	21.3
Gui, L [24]	China	Single-arm: K + TP	20	80	6.9	NA
Our study	China	Single-arm: PD-1 Ab + Taxanes	154	50.6	8.7	16.7

Note: Some clinical study protocols are unnamed and are referred to by the first author’s name in this table; Abbreviations for drugs in the groups: K: Pembrolizumab, PF: Platinum combined with fluorouracil, TP: Albumin-bound taxanes combined with cisplatin

ISSN: 1477-7819